Search

everythinglearnresearchcommunity

for

Search:↓

A new mutation in the HJV gene was found in a young woman with juvenile hemochromatosis, causing unusual symptoms like secondary hypothyroidism.

Asiasari radix extract may be a potential treatment for melanoma because it selectively triggers cell death in melanoma cells by affecting p53 regulation.

Targeting Keratin 17 may help overcome cancer therapy resistance.

Sirolimus and propranolol may reduce abnormal cell growth and improve lymphatic malformations in children.

Pexidartinib often causes liver issues and fatigue, especially in women.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.

Doxorubicin can block blood vessels from hair follicles, reducing skin tumor growth.

UV light helped human hair transplants survive in mice without broad immunosuppression.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

ITK inhibitors may effectively treat alopecia areata.

Finasteride and dutasteride might lower melanoma risk.

JAK inhibitors do not increase cancer risk in severe alopecia areata compared to traditional treatments.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.

Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.

Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.

Imatinib can cause hair loss due to lichen planopilaris.

Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.

Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

The treatment was effective for advanced non-Hodgkin's lymphomas.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Moles may stop growing because of cell cooperation, not just because of aging cells.

Ruxolitinib helped a patient with alopecia areata regrow hair.

PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.